223. Safronetz D, Ebihara H, Feldmann H, Hooper JW. The Syrian hamster model of hantavirus pulmonary syndrome. *Antiviral Res.* (2012) 95:282-92. doi: 10.1016/j.antiviral.2012.06.002

224. Seto T, Nagata N, Yoshikawa K, Ichii O, Sanada T, Saasa N, et al. Infection of Hantaan virus strain aa57 leading to pulmonary disease in laboratory mice. *Virus Res.* (2012) 163:284-90. doi: 10.1016/j.viruses.2011.10.016

225. Wei Z, Shimizu K, Sarii RS, Muthusinghe DS, Lokupathirage SMW, Nio-Kobayashi J, et al. Pathological studies on Hantaan virus-infected mice simulating severe hemorrhagic fever with renal syndrome. *Viruses*. (2022) 14. doi: 10.3390/v14102247

226. Golden JW, Hammerbeck CD, Mucker EM, Brocato RL. Animal models for the study of rodent-borne hemorrhagic fever viruses: arenaviruses and hantaviruses. *BioMed Res Int.* (2015) 2015:7939257

227. Hartman AL, Myler PJ. Bunyavirales: scientific gaps and prototype pathogens for a large and diverse group of zoonotic viruses. *J Infect Dis.* (2023) 228:5376-S89. doi: 10.1093/infdis/jiac338

228. Smith DR, Holbrook MR, Gowen BB. Animal models of viral hemorrhagic fever. *Antiviral Res.* (2014) 112:59-79. doi: 10.1016/j.antiviral.2014.10.001

229. Kim GR, McKee KT. Pathogenesis of Hantaan virus infection in suckling mice: clinical, virologic, and serologic observations. *Am J Trop Med Hygiene*. (1985) 34:388-95. doi: 10.4269/ajtmh.1985.34.388

230. Zhang XK, Takashima I, Mori F, Hashimoto N. Comparison of virulence between two strains of rattus serotype hemorrhagic fever with renal syndrome (HFRS) virus in newborn rats. *Microbiol Immunol*. (1989) 33:195-205. doi: 10.1111/j.1348-0421.1989.tb01513.x

231. Wichmann D, Gröne H-J, Frese M, Pavlovic J, Anheier B, Haller O, et al. Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice. *J Virol.* (2002) 76:8890-9. doi: 10.1128/jvi.76.17.8890-8899.2002

232. Ma R, Zhang X, Shu J, Liu Z, Sun W, Hou S, et al. Nlrc3 knockout mice showed renal pathological changes after HTNV infection. *Front Immunol.* (2021) 12:692509. doi: 10.3389/fimmu.2021.692509

233. Lopez R, Vial C, Graf J, Calvo M, Ferres M, Mertz G, et al. Platelet count in patients with mild disease at admission is associated with progression to severe hantavirus cardiopulmonary syndrome. *Viruses*. (2019) 11. doi: 10.3390/v11080693

234. Perley CC, Brocato RL, Kwilas SA, Daye S, Moreau A, Nichols DK, et al. Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantaviruses. *PloS One*. (2019) 14:e0216700. doi: 10.1371/journal.pone.0216700

235. Sanada T, Kariwa H, Nagata N, Tanikawa Y, Seto T, Yoshimatsu K, et al. Puumala virus infection in Syrian hamsters (Mesocricetus auratus) resembling hantavirus infection in natural rodent hosts. *Virus Res.* (2011) 160:108-19. doi: 10.1016/j.virusres.2011.05.021

236. Groen J, Gerding M, Koeman JP, Roholl PJ, van Amerongen G, Jordans HG, et al. A macaque model for hantavirus infection. *J Infect Dis.* (1995) 172:38-44. doi: 10.1093/infdis/172.1.38

237. Klingström J, Plyusnin A, Vaheri A, Lundkvist Å. Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. *J Virol.* (2002) 76:444-9. doi: 10.1128/jvi.76.1.444-449.2002

238. Sironen T, Klingström J, Vaheri A, Andersson LC, Lundkvist A, Plyusnin A. Pathology of Puumala hantavirus infection in macaques. *PloS One*. (2008) 3:e3035. doi: 10.1371/journal.pone.0003035

239. Dowall SD, Graham VA, Aram M, Findlay-Wilson S, Salguero FJ, Emery K, et al. Hantavirus infection in type I interferon receptor-deficient (A129) mice. *J Gen Virol.* (2020) 101:1047-55. doi: 10.1099/jgv.0.001470

240. Kobak L, Raftery MJ, Voigt S, Kühl AA, Kilic E, Kurth A, et al. Hantavirus-induced pathogenesis in mice with a humanized immune system. *J Gen Virol.* (2015) 96:1258-63. doi: 10.1099/vir.0.000087

241. Rissmann M, Noack D, Spliethof TM, Vaes VP, Stam R, van Run P, et al. A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies. *PloS Pathog.* (2025) 21:e1012875. doi: 10.1371/journal.ppat.1012875

242. Raftery MJ, Lalwani P, Lutteke N, Kobak L, Giese T, Ulrich RG, et al. Replication in the mononuclear phagocyte system (Mps) as a determinant of hantavirus pathogenicity. *Front Cell Infect Microbiol.* (2020) 10:281. doi: 10.3389/fcimb.2020.00281

243. Iheozor-Ejiofor R, Vapalahti K, Sironen T, Levanov L, Hepojoki J, Lundkvist Å, et al. Neutralizing antibody titers in hospitalized patients with acute puumala orthohantavirus infection do not associate with disease severity. *Viruses* (2022) 14 (5). doi: 10.3390/v14050901

244. Linderholm M, Ahlm C, Settergren B, Waage A, Tärnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and il-10 in patients with hemorrhagic fever with renal syndrome. *J Infect Dis.* (1996) 173:38-43. doi: 10.1093/infdis/173.1.38

245. Schmaljohn C. Vaccines for hantaviruses. *Vaccine*. (2009) 27 Suppl 4:D61-4. doi: 10.1016/j.vaccine.2009.07.096

246. Boudreau EF, Josleyn M, Ullman D, Fisher D, Dalrymple L, Sellers-Myers K, et al. A phase I clinical trial of Hantaan virus and Puumala virus M-segment DNA

vaccines for hemorrhagic fever with renal syndrome. *Vaccine*. (2012) 30:1951-8. doi: 10.1016/j.vaccine.2012.01.024

247. Avižinienė A, Kučinskaitė-Kodzė I, Petraitytė-Burneikienė R, Žirvlienė A, Mertens ML, Schmidt S, et al. Characterization of a panel of cross-reactive hantavirus nucleocapsid protein-specific monoclonal antibodies. *Viruses*. (2023) 15. doi: 10.3390/v15020532

248. Lee HW, Chang Na. *Development of vaccine against Hemorrhagic Fever with Renal Syndrome*. (1988) 6:143-8. Butterworth & Co. (Publishers) Ltd.

249. Sohn YM, Rho HO, Park MS, Kim JS, Summers PL. Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavirus): consideration of active immunization in South Korea. *Yonsei Med J.* (2001) 42:278-84. doi: 10.3349/ymj.2001.42.3.278

250. Bae J-M. Introduction of vaccinomics to develop personalized vaccines in light of changes in the usage of Hantaan virus vaccine (Hantavirus®) in Korea. *J Prev Med Public Health.* (2019) 52:277-80. doi: 10.3961/jpmph.19.018

251. Cho H-W, Howard CR, Lee H-W. Review of an inactivated vaccine against hantaviruses. *Intervirology*. (2002) 45:328-33. doi: 10.1159/000067925

252. Park K, Kim CS, Moon K-T. Protective effectiveness of hantavirus vaccine. *Emerging Infect Dis.* (2004) 10:2218-20. doi: 10.3201/eid1012.040684

253. Yi Y, Park H, Jung J. Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome. *Kidney Res Clin Pract.* (2018) 37:366-72. doi: 10.23876/j.krcp.18.0044

254. Song JY, Woo HJ, Cheong HJ, Noh JY, Baek LJ, Kim WJ. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavirus™) in healthy adults. *Vaccine*. (2016) 34:1289-95. doi: 10.1016/j.vaccine.2016.01.031

255. Song JY, Jeong HW, Yun JW, Lee J, Woo HJ, Bae J-Y, et al. Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavirus): A multi-center phase III clinical trial in healthy adults. *Vaccine*. (2020) 38:8016-23. doi: 10.1016/j.vaccine.2020.10.035

256. Cho HW, Howard CR. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavirus). *Vaccine*. (1999) 17:2569-75. doi: 10.1016/s0264-410x (99)00057-2

257. Brocato RL, Hooper JW. Progress on the prevention and treatment of hantavirus disease. *Viruses*. (2019) 11. doi: 10.3390/v11070610

258. Afzal S, Ali L, Batool A, Afzal M, Kanwal N, Hassan M, et al. Hantavirus: an overview and advancements in therapeutic approaches for infection. *Front Microbiol.* (2023) 14:1233433. doi: 10.3389/fmicb.2023.1233433

259. Dzagurova TK, Siniugina AA, Ishmukhametov AA, Egorova MS, Kurashova SS, Balovneva MV, et al. Pre-clinical studies of inactivated polyvalent HFRS vaccine. *Front Cell Infect Microbiol.* (2020) 10:545372. doi: 10.3389/fcimb.2020.545372

260. Kurashova SS, Ishmukhametov AA, Dzagurova TK, Egorova MS, Balovneva MV, Nikitin NA, et al. Various adjuvants effect on immunogenicity of Puumala virus vaccine. *Front Cell Infect Microbiol.* (2020) 10:545371. doi: 10.3389/fcimb.2020.545371

261. Lundkvist A, Kallio-Kokko H, Sjölander KB, Lankinen H, Niklasson B, Vaheri A, et al. Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. *Virology*. (1996) 216:397-406. doi: 10.1006/viro.1996.0075

262. Carvalho Nicacio Cd, Sällberg M, Hultgren C, Lundkvist Å. T-helper and humoral responses to Puumala hantavirus nucleocapsid protein: identification of T-helper epitopes in a mouse model. *J Gen Virol.* (2001) 82:129-38. doi: 10.1099/0022-1317-82-1-129

263. Kehm R, Jakob NJ, Welzel TM, Tobiasch E, Viczian O, Jock S, et al. Expression of immunogenic Puumala virus nucleocapsid protein in transgenic tobacco and potato plants. *Virus Genes.* (2001) 22:73-83. doi: 10.1023/a:1008186403612

264. Carvalho Nicacio Cd, Della Gonzalez Valle M, Padula P, Björling E, Plyusnin A, Lundkvist Å. Cross-Protection against Challenge with Puumala virus after Immunization with Nucleocapsid Proteins from Different Hantaviruses. *J Virol.* (2002) 76:6669-77. doi: 10.1128/jvi.76.13.6669-6677.2002

265. Dargeviciute A, Brus Sjölander K, Sasnauskas K, Krüger DH, Meisel H, Ulrich R, et al. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. *Vaccine*. (2002) 20:3523-31. doi: 10.1016/s0264-410x(02)00341-9

266. Khattak S, Darai G, Rösen-Wolff A. Puumala virus nucleocapsid protein expressed in transgenic plants is not immunogenic after oral administration. *Virus Genes.* (2004) 29:109-16. doi: 10.1023/b:Viru.0000032794.24032.72

267. Maes P, Clement J, Cawue B, Bonnet V, Keyaerts E, Robert A, et al. Truncated recombinant Puumala virus nucleocapsid proteins protect mice against challenge in vivo. *Viral Immunol.* (2008) 21:49-60. doi: 10.1089/vim.2007.0059

268. Zhao C, Sun Y, Zhao Y, Wang S, Yu T, Du F, et al. Immunogenicity of a multi-epitope DNA vaccine against hantavirus. *Hum Vaccines Immunotherapeutics.* (2012) 8:208-15. doi: 10.4161/hv.18389

269. Koletzki D, Schirmbeck R, Lundkvist A, Meisel H, Krüger DH, Ulrich R. DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection. *J Biotechnol.* (2001) 84:73-8. doi: 10.1016/s0168-1656(00)00329-1

270. Bucht G, Sjölander KB, Eriksson S, Lindgren L, Lundkvist A, Elgh F. Modifying the cellular transport of DNA-based vaccines alters the immune response to hantavirus nucleocapsid protein. *Vaccine.* (2001) 19:3820-9. doi: 10.1016/s0264-410x(01)00151-7
271. Lindkvist M, Lahti K, Lilliehöök B, Holmström A, Ahlm C, Bucht G. Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins. Vaccine. (2007) 25:1690–9. doi: 10.1016/j.vaccine.2006.09.082

272. Spik KW, Badger C, Mathiessen I, Tjelle T, Hooper JW, Schmaljohn C. Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters. Vaccine. (2008) 26:5177–81. doi: 10.1016/j.vaccine.2008.03.097

273. Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys. J Virol. (2001) 75:8469–77. doi: 10.1128/jvi.75.18.8469-8477.2001

274. Ulrich R, Lundkvist A, Meisel H, Koletzki D, Sjölander KB, Gelderblom HR, et al. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine. (1998) 16:272–80. doi: 10.1016/s0264-410x(97)00172-2

275. Shkair L, Garanina EE, Martynova EV, Kolesnikova AI, Arkhipova SS, Titova AA, et al. Immunogenic properties of MVs containing structural hantaviral proteins: an original study. *Pharmaceutics*. (2022) 14. doi: 10.3390/pharmaceutics14010093

276. Shkair L, Sharma D, Hamza S, Garanina E, Shakirova V, Khaertynova I, et al. Cross-reactivity of hantavirus antibodies after immunization with PUUV antigens. *Biotechnol Appl Biochem.* (2024) 71:1139–53. doi: 10.1002/bab.2604

277. Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, et al. A phase I clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. *Clin Microbiol Infect.* (2014) 20 Suppl 5:110–7. doi: 10.1111/1469-0691.12553

278. Hooper J, Paolino KM, Mills K, Kwilas S, Josleyn M, Cohen M, et al. A phase 2a randomized, double-blind, dose-optimizing study to evaluate the immunogenicity and safety of a bivalent DNA vaccine for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Vaccines. (2020) 8. doi: 10.3390/vaccines8030377

279. Hooper JW, Kwilas SA, Josleyn M, Norris S, Hutter JN, Hamer M, et al. Phase I clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection. *NPJ Vaccines*. (2024) 9. doi: 10.1038/s41541-024-00998-7

280. Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP. Immunity to hantavirus challenge in meriones unguiculatus induced by vaccinia-vectored viral proteins. *Am J Trop Med Hygiene*. (1992) 47:397–404. doi: 10.4269/ajtmh.1992.47.397

281. Engdahl TB, Crowe JE. Humoral immunity to hantavirus infection. *mSphere*. (2020) 5. doi: 10.1128/mSphere.00482-20

282. Elgh F, Linderholm M, Wadell G, Tärnvik A, Juto P. Development of humoral cross-reactivity to the nucleocapsid protein of heterologous hantaviruses in nephropathia epidemica. *FEMS Immunol Med Microbiol*. (1998) 22:309–15. doi: 10.1111/j.1574-695X.1998.tb01220.x

283. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. *Hum Vaccines Immunotherapeutics*. (2015) 11:477–88. doi: 10.1080/21645515.2014.1004026

284. Maes P, Keyaerts E, Bonnet V, Clement J, Avsic-Zupanc T, Robert A, et al. Truncated recombinant Dobrava hantavirus nucleocapsid proteins induce strong,

long-lasting immune responses in mice. *Intervirology*. (2006) 49:253–60. doi: 10.1159/000093454

285. Hoenen T, Groseth A, Kok-Mercado Fd, Kuhn JH, Wahl-Jensen V. Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. *Antiviral Res.* (2011) 91:195–208. doi: 10.1016/j.antiviral.2011.06.003

286. Conzelmann K-K, Meyers G. Genetic engineering of animal RNA viruses. *Trends Microbiol*. (1999) 4:386–93. doi: 10.1016/0966-842x(96)10062-7

287. Stobart CC, Moore ML. RNA virus reverse genetics and vaccine design. *Viruses*. (2014) 6:2531–50. doi: 10.3390/v6072531

288. Walpita P, Flick R. Reverse genetics of negative-stranded RNA viruses: A global perspective. *FEMS Microbiol Lett*. (2005) 244:9–18. doi: 10.1016/j.femsle.2005.01.046

289. Zobel A, Neumann G, Hobom G. RNA polymerase I catalysed transcription of insert viral cDNA. *Nucleic Acids Res.* (1993) 21:3607–14. doi: 10.1093/nar/21.16.3607

290. Fuerst TR, Niles EG, Studier FW, Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. *Proc Natl Acad Sci USA*. (1986) 83:8122–6. doi: 10.1073/pnas.83.21.8122

291. Tercero B, Makino S. Reverse genetics approaches for the development of bunyavirus vaccines. *Curr Opin Virol*. (2020) 44:16–25. doi: 10.1016/j.coviro.2020.05.004

292. Brown KS, Ebihara H, Feldmann H. Development of a minigenome system for Andes virus, a New World hantavirus. *Arch Virol*. (2012) 157:2227–33. doi: 10.1007/s00705-012-1401-0

293. Welzel TM, Kehm R, Tidona CA, Muranyi W, Darai G. Stable expression of nucleocapsid proteins of Puumala and Hantaan virus in mammalian cells. *Virus Genes*. (1998) 17:185–98. doi: 10.1023/a:1008076926061

294. Flick K, Hooper JW, Schmaljohn CS, Pettersson RF, Feldmann H, Flick R. Rescue of Hantaan virus minigenomes. *Virology*. (2003) 306:219–24. doi: 10.1016/s0042-6822(02)00070-3

295. Kell AM. Innate immunity to orthohantaviruses: could divergent immune interactions explain host-specific disease outcomes? *J Mol Biol*. (2021) 434:167230. doi: 10.1016/j.jmb.2021.167230

296. Klempa B. Reassortment events in the evolution of hantaviruses. *Virus Genes*. (2018) 54:638–46. doi: 10.1007/s11262-018-1590-z

297. Handke W, Oelschlegel R, Franke R, Wiedemann L, Krüger DH, Rang A. Generation and characterization of genetic reassortants between Puumala and Prospect Hill hantavirus *in vitro*. *J Gen Virol*. (2010) 91:2351–9. doi: 10.1099/vir.0.021139-0

298. McElroy AK, Smith JM, Hooper JW, Schmaljohn CS. Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters. *Virology*. (2004) 326:130–9. doi: 10.1016/j.virol.2004.05.018

299. Cheng E, Wang Z, Mir MA. Interaction between hantavirus nucleocapsid protein (N) and rna-dependent RNA polymerase (RdRp) mutants reveals the requirement of an N-RdRp interaction for viral RNA synthesis. *J Virol*. (2014) 88:8706–12. doi: 10.1128/jvi.00405-14